January 31, 2024
None
National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified organizations (NAICS Code 541715) having in-house capability to provide in vivo evaluation, in rodents, of potential pharmacotherapies that would specifically prevent relapse to cocaine and other drugs of abuse. It also provides support for the development of methods and protocols to be used for compound evaluation including drug self-administration.
This project will be utilized by the Division of Therapeutics and Medical Consequences (DTMC), to determine the in vivo efficacy of novel compounds in animal models of relapse. This includes the following tests in animals trained to self-administer cocaine or other drugs of abuse; (1) the ability of a test compound to block or reduce footshock- or other stressor-induced reinstatement of responding after a period of experimental extinction, (2) the ability of a test compound to block or reduce drug-priming-induced reinstatement of responding after a period of extinction, and (3) the ability of a test compound to block or reduce the effects of a conditioned cue (previously paired with drug) to reinstate responding for cocaine after a period of extinction.
An integral part of this work is to develop methods and to design and implement protocols for the evaluation of test compounds. A number of laboratories have used some of the methodologies described in the literature. While recognizing the need for methods development, NIDA anticipates that by Option Period 1, if Options are exercised, the majority of the Contractor’s efforts will be devoted to test compound evaluations. The Contractor shall identify and acquire standard compounds that merit the aforementioned types of evaluation. In addition, if NIDA exercises specific contract options, this contract shall support follow-up rodent pharmacology studies of compounds identified as promising potential drug-dependence treatment agents including through the use of drug self-administration studies. The details of these latter studies cannot be specified before contract award; they will depend upon specific successes in NIDA’s medication discovery efforts and scientific advances in the general field of drug abuse research. Written reports documenting the study findings are the anticipated end products of this contract.
Mandatory Criteria:
Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess prior to award US Department of Justice Drug Enforcement Administration (DEA) Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess or demonstrate the ability to obtain prior to award DEA registration for Schedule I controlled substances.
The offeror must demonstrate its understanding and compliance with the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals (Policy) and the Guide for Care and Use of Laboratory Animals (Guide). The NIH will not make an award for research involving live vertebrate animals until the offeror and all performance sites where animal work will be conducted have (1) an approved Animal Welfare Assurance, (2) completed a Vertebrate Animals Section (VAS), and (3) the offeror has provided verification of Institutional Animal Care and Use (IACUC) approval for all proposed animal activities.
Notice:
We anticipate the award of one cost-reimbursement, level of effort contract for a base period of one year with four one-year options to extend performance. The contract will include additional quantity options.
RFP No. 75N95024R00011 will be available electronically on or about February 5, 2024. You can access the RFP through the sam.gov (URL: http://sam.gov) or through the NIDA website: (URL: http://www.drugabuse.gov/funding/funding-opportunities/nida-requests-contract-proposals-rfps). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due 30 days from the release date. NIDA anticipates a July 2024 award date. NIDA will consider proposals submitted by any responsible offeror.
Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government’s requirement with a commercial item within 15 days of this notice.
Llakim Dubroff, Contract Specialist
National Institute on Drug Abuse (NIDA)
Phone: (301) 443-6677
Email: Llakim.Dubroff@nih.gov
Tracy Cain, Contracting Officer
National Institute on Drug Abuse (NIDA)
Phone: (301) 443-6677
Email: Tracy.Cain@nih.gov
and Human Services (HHS)
